Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is 158.20% higher on its value in year-to-date trading and has touched a low of $1.76 and a high of $13.17 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARQT stock was last observed hovering at around $8.31 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $8.34, the stock is -11.93% and -14.76% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.55 million and changing 0.36% at the moment leaves the stock -7.02% off its SMA200. ARQT registered 238.34% gain for a year compared to 6-month gain of -4.58%. The firm has a 50-day simple moving average (SMA 50) of $9.8067 and a 200-day simple moving average (SMA200) of $8.946525.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -13.40% loss in the last 1 month and extending the period to 3 months gives it a -14.64%, and is -10.80% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.65% over the week and 5.91% over the month.
Arcutis Biotherapeutics Inc (ARQT) has around 296 employees, a market worth around $974.86M and $132.06M in sales. Profit margin for the company is -150.51%. Distance from 52-week low is 373.86% and -36.67% from its 52-week high. The company has generated returns on investments over the last 12 months (-50.55%).
with sales reaching $37.62M over the same period.The EPS is expected to grow by 59.90% this year, but quarterly earnings will post 178.90% year-over-year. Quarterly sales are estimated to grow 14.60% in year-over-year returns.
Arcutis Biotherapeutics Inc (ARQT) Top Institutional Holders
249.0 institutions hold shares in Arcutis Biotherapeutics Inc (ARQT), with institutional investors hold 113.83% of the company’s shares. The shares outstanding are 116.89M, and float is at 101.69M with Short Float at 26.68%. Institutions hold 111.35% of the Float.
The top institutional shareholder in the company is JENNISON ASSOCIATES LLC with over 11.57 million shares valued at $107.62 million. The investor’s holdings represent 9.3712% of the ARQT Shares outstanding. As of 2024-06-30, the second largest holder is SUVRETTA CAPITAL MANAGEMENT, LLC with 10.0 million shares valued at $$93.04 million to account for 8.1021 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 9.82 million shares representing 7.95% and valued at over $91.3 million, while BLACKROCK INC. holds 7.7647 of the shares totaling 8.62 million with a market value of $80.19 million.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
The most recent transaction is an insider sale by Welgus Howard G., the company’s Director. SEC filings show that Welgus Howard G. sold 10,000 shares of the company’s common stock on Oct 01 ’24 at a price of $9.26 per share for a total of $92616.0. Following the sale, the insider now owns 0.18 million shares.
Arcutis Biotherapeutics Inc disclosed in a document filed with the SEC on Oct 02 ’24 that Edwards Larry Todd (SVP Chief Commercial Officer) sold a total of 3,725 shares of the company’s common stock. The trade occurred on Oct 02 ’24 and was made at $10.01 per share for $37295.0. Following the transaction, the insider now directly holds 0.14 million shares of the ARQT stock.
Still, SEC filings show that on Oct 02 ’24, Edwards Larry Todd (Officer) Proposed Sale 3,725 shares at an average price of $10.01 for $37295.0. The insider now directly holds shares of Arcutis Biotherapeutics Inc (ARQT).
